The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Big pharmaceutical companies like Bristol Myers Squibb, Merck and Johnson & Johnson face ... further threaten the companies' ...

We came across a bullish thesis on Merck & Co., Inc. (MRK) on Disruptive analytics’s Substack by Magnus Ofstad. In this ...

Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsConstantin Fest - Head of Investor ...

The company has previously reached settlement agreements with more than 20 other generics ... a big victory for Merck, given that Januvia remains its third best-selling product after cancer ...

Over more than 20 years in the pharma industry ... and to direct R&D efforts where they can best help patients. To achieve this objective, in 2017, Merck launched a first-of-its-kind initiative ...

These stocks near 52-week lows could be ready to rebound.

We recently compiled a list of the 10 Best Low Volatility Stocks to Invest in Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against the other low ...

The top 20 biopharmaceutical companies demonstrated signs of recovery during the third quarter (Q3) of 2024 as investor ...

The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers ...